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Objective: To develop a more age-appropriate spirometric definition of chronic obstructive
pulmonary disease (COPD) among older persons.
Methods: Using data from the Third National Health and Nutrition Examination Survey
(NHANES III), we developed a two-part spirometric definition of COPD in older persons, aged
65e80 years, that 1) determines a cut-point for the ratio of forced expiratory volume in 1 s to
forced vital capacity (FEV1/FVC) based onmortality risk; and 2) among persons below this critical
FEV1/FVC threshold, determines cut-points for the FEV1, expressed as a standardized residual
percentile (SR-tile) and based on the prevalence of respiratory symptoms and mortality risk.
Measurements included spirometry, healthquestionnaires, andmortality (National Death Index).
Results: There were 2480 older participants with a mean age of 71.7 years; 1372 (55.4%) had
a smoking history, 1097 (44.2%) had respiratory symptoms and, over the course of 12-years,
868 (35.0%) had died. Among participants with an FEV1/FVC< .70 and FEV1< 5th SR-tile, repre-
senting 7.7% of the cohort, the risk of death was doubled (adjusted hazard ratio, 2.01; 95% confi-
dence interval [CI], 1.60e2.54). Among participants with an FEV1/FVC< .70 and FEV1< 10th SR-
tile, representing 13.4% of the cohort, the prevalence of respiratory symptoms was elevated
(adjusted odds ratio, 2.44; CI, 1.79e3.33).
Conclusion: In a large, nationally representative sample of community-living older persons,
defining COPD based on an FEV1/FVC< .70, with FEV1 cut-points at the 10th and 5th SR-tiles,
identifies individuals with an increased prevalence of respiratory symptoms and an increased risk
of death, respectively.
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Chronic obstructive pulmonary disease (COPD), a leading
cause of disability and death worldwide, is defined by chronic
airflow limitation that is not fully reversible.1e9 The airflow
limitation is established spirometrically, based solely on
a reduced ratio of forced expiratory volume in 1 s (FEV1) to
forced vital capacity (FVC), with severity subsequently cate-
gorized according to the FEV1.
2e9 This strategy for defining
COPD has a physiological basis because airflow limitation
increases the risk of death and usually precedes the onset of
dyspnea or exercise intolerance.10,11 In contrast, defining
COPD on the basis of disease criteria alone (e.g. chronic
bronchitis) lacks diagnostic accuracy, because cough and
sputum production may occur in the absence of airflow limi-
tation and are not independent predictors of death.10e12
Current spirometric guidelines are potentially problem-
atic, however, for at least three reasons. First, the threshold
that establishes a reduced FEV1/FVC remains con-
troversial.6e8 For example, the Global Initiative for Obstruc-
tive Lung Disease (GOLD) and the American College of
Physicians (ACP) advocate an FEV1/FVC threshold based on
a fixed-ratio,4,13 but this by itself cannot distinguish clinically-
significant pathology from normal age-related increases in
airflow limitation.7 Alternatively, the American Thoracic
Society (ATS) and the European Respiratory Society (ERS)
advocate an FEV1/FVC threshold based on the lower limit of
normal (LLN),9 but this is derived from regression equations
that have limited explanatory ability when applied to an
elderly population (i.e., R2 range of .03e.08).8,14,15 Second,
thepresentmethodof reporting theFEV1aspercentpredicted
(%Pred) is fundamentally flawed, because it does not account
for differences in the variability of the reference group across
the lifespan.16,17 As a result, a given FEV1 %Pred value is not
equivalent for all persons regardless of age, height, sex, and
ethnicity.16,17 Third, current spirometric guidelines, in
general, lack clinical validation regarding importantmeasures
such as mortality and respiratory symptoms.4,9,13
These problems with current spirometric guidelines are
most evident among older persons. Specifically, conven-
tional cut-points for the FEV1/FVC ratio yield prevalence
rates for COPD (in the U.S.) that range widely from 16% to
42%, with most affected individuals subsequently catego-
rized by the FEV1 %Pred as having ‘‘mild’’ COPD.
6,7 Hence,
current spirometric guidelines may lead to misclassification
(mainly over-diagnosis) of COPD among older persons and,
in turn, potentially compromise patient care.7,13,18
As an alternative spirometric strategy, we propose that
COPD be defined by a two-step process that 1) determines
a cut-point for the FEV1/FVC based on mortality risk; and 2)
among persons below this critical FEV1/FVC threshold,
determines cut-points for the FEV1, expressed as a stan-
dardized residual percentile (SR-tile) and based on the
prevalence of respiratory symptoms and mortality risk. An
SR-tile is simply a Z-score that has been converted to
a percentile,16,17 and is analogous to what is currently
reported for bone mineral density testing.19 Importantly,
the SR-tile method accounts for variability in age, height,
sex, and ethnicity.16,17 In the present study, we have applied
our strategy for defining COPD in a large nationally repre-
sentative sample of community-living older persons, whichincluded a large proportion of women and minorities, and
discuss how this approach is more clinically meaningful than
those provided in published guidelines.4,9,13
Methods
Study population
We used data from the Third National Health and Nutrition
Examination Survey (NHANES III), a nationally representative
sample of Americans assembled in 1988e1994, withmortality
surveillance through December 31, 2000.20,21 Our source
population included 2480 community-living NHANES III
participants, aged 65e80 years, who were white, African-
American, or Mexican-American, had no self-reported
asthma, and had completed a health questionnaire, a brief
cognitive assessment, and at least two ATS acceptable spiro-
metricmaneuvers.22Asper currentATS recommendations,we
did not exclude participants based on spirometric reproduc-
ibility criteria.3
Clinical measures
As described elsewhere,20 NHANES III recorded the pres-
ence of respiratory symptoms in the prior 12 months,
including chronic cough or sputum production lasting 3 or
more consecutive months, dyspnea on exertion, and
wheezing or ‘‘whistling in the chest’’. Other clinical data
included chronic conditions, including self-reported,
physician-diagnosed COPD and asthma, as well as smoking
history, self-reported health status, body mass index (BMI),
and cognitive function. Memory impairment was defined as
a score less than 2 on delayed recall of a 3-item word list or
a score less than 4 on delayed recall from a 6-item story.
Spirometry
NHANES III utilized a customized Ohio Sensormed 827 dry
rolling seal spirometer.20 After calibration, each participant
performed 5e8 FVC maneuvers, with the goal of meeting
ATS criteria.20,22
As shown in the appendix, and following current guide-
lines,9 we determined regression equations in an NHANES III
reference group of age-matched never-smokers, with no
chronic conditions and no respiratory symptoms. Also as per
guidelines,9 we used age and height as predictor variables for
FEV1 and FVC within each sex and ethnic group. Our subse-
quent procedures, however, differed from those of prior
studies that calculated the FEV1 as %Pred (i.e., measured/
predicted 100).4,5,6,8 Instead, in a reference group of age-
matched, healthy never-smokers, we calculated the constant
that quantified the spread of the reference data, namely the
standard deviation of the residuals. (A ‘‘residual’’ is the
difference between a measured and predicted value.) Based
on the regression equations and the spread of the reference
data, we then expressed the measured FEV1 of each partici-
pant as a standardized residual (SR), calculated as [(measur-
ed predicted)/(standard deviation of the residuals)];
a percentile based on the SRwas subsequently computed (SR-
tile).16,17 To illustrate, an SR of 1.64 corresponds to the 5th
Table 1 Characteristics of the study population.
Characteristic nZ 2,480
Age, mean (SD), years 71.7 (4.5)
Females, No. (%) 1252 (50.5)
Ethnicity, No. (%)
White 1497 (60.4)
African-American 517 (20.8)
Mexican-American 466 (18.8)
Education, mean (SD), years 9.7 (4.4)
Smoking status, No. (%)
Never 1108 (44.7)
Former 1001 (40.4)
Current 371 (15.0)
Chronic conditions, No. (%)a
Hypertension 1194 (48.3)
Arthritis 1107 (44.6)
Diabetes mellitus 407 (16.4)
Myocardial infarction 272 (11.1)
Chronic obstructive
pulmonary disease
214 (8.6)
Congestive heart failure 205 (8.3)
Cancerb 199 (8.0)
Stroke 173 (7.0)
Fair-to-poor self-reported
health, No. (%)
824 (33.3)
Respiratory symptoms,
No. (%)c
1097 (44.4)
Memory impairment,
No. (%)d
859 (34.9)
Abbreviation: SDZ standard deviation.
a Self-reported, physician-diagnosed.
b Minor skin cancers are not included.
c Included cough or sputum production, wheezing, or exertional
dyspnea.
d Defined by a score of 0e1 on delayed recall of a 3-item word
list or a score of 0e3 on delayed recall from a 6-item story.
1470 C.A. Vaz Fragoso et al.percentile, an SR of 0 corresponds to the 50th percentile,
and an SR of 1.64 corresponds to the 95th percentile.16,17
By standardizing the residuals to the spread of the reference
data, the SR method accounts for variability due to age,
sex, height, and ethnicity and reports FEV1 SR-tile values
on an easy-to-interpret scale of 0e100, whereas %Pred
does not.16,17
Wenext classifiedparticipants basedon their SR-tile values
for FEV1, using cut-points established for the FEV1 %Pred (80,
50, and 30) by the Global Initiative for Obstructive Lung
Disease (GOLD).4 We modified these cut-points to 50, 30, 10,
and 5 SR-tiles because only a small number of NHANES III
participants with FEV1/FVC values below the critical
threshold, as defined below, had an FEV1> 80th SR-tile
(nZ 21) whereas a large number had an FEV1< 30th SR-tile
(nZ 321).
Lastly, we calculated the LLN for the FVC, to help define
the referent group for our mortality risk analysis, i.e., the
FVC criterion was used to exclude persons with restrictive
lung disease.8
We do not report the LLN for the FEV1/FVC because pre-
dicted values could not be determined reliably. In contrast to
the FEV1 and FVC, regression equations for the FEV1/FVC had
very low R2 values, ranging from 0.01 to 0.07, with only one
exception (the value for Mexican-females was 0.15). This lack
of explanatory capacity persisted whenwe analyzed the ratio
of the FEV1 to the forced expiratory volume in 6 s (FEV6),
whichyieldedR2 valuesof 0.01e0.08. These results are similar
to those published in other cohorts of older persons.14,15
Primary outcome
Our primary outcome was all-cause mortality, ascertained
from a public-use linked mortality file that contains infor-
mation based on the National Death Index, with follow-up
through December 31, 2000.21 Vital status was available on
all but one participant.21
Statistical analysis
SUDAAN version 9.0.1 (Research Triangle Park) was used to
estimate hazard ratios (Cox proportional hazards analysis)
and odds ratios (logistic regression), with a p-value< 0.05
(two-sided) denoting statistical significance.23 Proportional
hazard assumptions for survival models were tested using
interaction terms crossing the time-to-event outcome with
each variable in the multivariable model. If significant at
the 0.05 level, these interaction terms were retained in the
final model. The incidence rate and 95% confidence interval
(CI) for death were expressed in personeyears. Participants
who had not died were censored at the end of the follow-up
period.
As a first step, we varied the cut-point for the FEV1/FVC
in 0.05 decrements below a ratio of 0.80, and fit separate
Cox regression models for all-cause mortality, each
adjusted for age, height, sex, ethnicity, smoking history,
BMI, chronic conditions, self-reported health status, and
cognition. Higher order effects were tested for the
continuous covariates and were included in the final models
if they met the forward selection criterion of p< 0.20.24
The first FEV1/FVC cut-point below 0.80 that yieldeda statistically significant increase in the risk of death was
termed the ‘‘critical’’ threshold.
Next, among participants with an FEV1/FVC below the
critical threshold, we evaluated time-to-death using the
KaplaneMeier method with strata defined according to FEV1
cut-points, expressed as SR-tile. We then determined the
independent association between the FEV1 SR-tile cut-points
and death using Cox proportional hazards, adjusted for the
same covariates as described earlier. The FEV1 SR-tile cut-
points were treated as nominal categories, with the referent
group including participants with normal pulmonary function,
definedbyanFEV1/FVC critical thresholdandanFVC LLN.
Similarly,wealsoevaluated theassociationsbetweenFEV1SR-
tile cut-points and the presence of respiratory symptoms, by
calculating odds ratios using logistic regression.
To enhance the interpretation of our findings, we eval-
uated the prevalence of smoking exposure and reduced
health status according to the FEV1 SR-tile cut-points
among participants with an FEV1/FVC below the critical
threshold, and we calculated the FEV1 %Pred values that
corresponded to these SR-tile cut-points.
Table 2 Adjusted hazard ratios for all-cause mortality according to FEV1/FVC cut-points (NZ 2406).
a
FEV1/FVC models
b No. (%) of participants
below cut-point
No. (%) of deaths
among participants below cut-point
Hazard ratio
for mortality (95% CI)
p-value
<.80 1941 (80.7) 693 (35.7) 1.07 (0.90, 1.28) .440
<.75 1376 (57.2) 529 (38.4) 1.11 (0.96, 1.28) .152
<.70 831 (34.5) 364 (43.8) 1.23 (1.03, 1.47) .020
<.65 454 (18.9) 229 (50.4) 1.33 (1.12, 1.58) .002
<.60 241 (10.0) 136 (56.4) 1.42 (1.15, 1.76) .002
<.55 136 (5.6) 92 (67.6) 1.67 (1.33, 2.09) <.001
Abbreviations: FEV1Z forced expiratory volume in 1 s; FVCZ forced vital capacity; CIZ confidence interval; BMIZ body mass index.
a 74 participants (3.0%) had missing covariates.
b Each FEV1/FVC cut-point represents a separate Cox regression model, adjusted for age, age
2, height, sex, ethnicity, smoking history,
BMI, BMI2, BMI3, memory impairment, self-reported health status by time interaction, and chronic conditions. The referent group for
each FEV1/FVC cut-point is the population above the specified cut-point.
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As shown in Table 1, our study population had a mean age of
approximately 72 years, with a majority being current or
former smokers. The five most common self-reported
chronic conditions were hypertension, arthritis, diabetes
mellitus, myocardial infarction, and chronic obstructive
pulmonary disease. About a third of the participants had
fair-to-poor health status and memory impairment,
respectively, and 44.4% endorsed respiratory symptoms.
Over the 12-year follow-up period, 868 (35.0%) participants
died, yielding a mortality rate of 4.6 per 100 personeyears
(95% confidence interval [CI] 4.3, 4.9).
Table 2 provides adjusted hazard ratios for all-cause
mortality according to the FEV1/FVC. An increased mortality
risk was first observed at a cut-point below .70, with anYears of Fo
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Figure 1 KaplaneMeier survival curves in participants with airflo
established by an FEV1/FVC< .70, with severity defined by FEV1 SR
<5th, 5e9th, 10e29th, 30e49th, and 50th SR-tiles was 179, 133, 2
group, which included 1488 participants, had normal pulmonary fun
normal. Abbreviations: FEV1Z forced expiratory volume in 1 s;
percentile.adjusted hazard ratio of 1.23 (95%CI, 1.03e1.47). Fig. 1
displays KaplaneMeier survival curves amongparticipantswith
an FEV1/FVC< .70, stratified by FEV1 SR-tile. Survival was
notably lower for participants with an FEV1< 5th SR-tile. As
shown inTable 3, a threshold effect formortalitywas observed
at an FEV1< 5th SR-tile, with an adjusted hazard ratio of 2.01
(95%CI, 1.60e2.54), representing 7.7% of the cohort.
Table 4 reports adjusted odds ratios for respiratory
symptoms, based on FEV1 SR-tile among participants with an
FEV1/FVC< .70 versus those with normal pulmonary func-
tion. A graded relationshipwas observed, with FEV1 stages at
<5th SR-tile and 5the9th SR-tiles, respectively, demon-
strating statistically significant elevations in the odds ratio.
When these two stages were combined, i.e., FEV1< 10th SR-
tile, the adjusted odds ratio for respiratory symptoms was
2.44 (95%CI, 1.79e3.33), representing 13.4% of the cohort.llow-Up
7 8 9 10 11 12 13
30-49th SR-tile
Referent Group
5-9th SR-tile
> 50th SR-tile
10-29th SR-tile
< 5th SR-Tile
w limitation, stratified by FEV1 SR-tile. Airflow limitation was
-tile. The number of participants at risk in the FEV1 groups of
81, 122, and 116, respectively, for a total of 831. The referent
ction defined by an FEV1/FVC .70 and an FVC lower limit of
FVCZ forced vital capacity; SR-tileZ standardized residual
Table 3 Adjusted hazard ratios for all-cause mortality according to FEV1 SR-tile, among participants with airflow limitation
versus those with normal pulmonary function (NZ 2319).a
Spirometric category No. (%) of participants No. (%) of deaths
among participants
Hazard ratio
for mortality (95% CI)b
p-value
Normal pulmonary
functionc
1488 (64.2) 429 (28.8) 1.00 e
Airflow limitationd FEV1 SR-tile
50th 116 (5.0) 46 (39.7) 1.12 (0.80, 1.58) .507
30the49th 122 (5.3) 40 (32.8) .85 (0.61, 1.19) .332
10the29th 281 (12.1) 114 (40.6) 1.12 (0.90, 1.40) .291
5the9th 133 (5.7) 53 (40.0) 1.06 (0.82, 1.39) .636
<5th 179 (7.7) 111 (62.0) 2.01 (1.60, 2.54) <.001
Abbreviations: FEV1Z forced expiratory volume in 1 s; SR-tileZ standardized residual percentile; FVCZ forced vital capacity;
CIZ confidence interval; BMIZ body mass index; LLNZ lower limit of normal.
a 74 participants (3.6%) had missing covariates and 87 (3.5%) were excluded because of restrictive pulmonary physiology, i.e., an
FEV1/FVC .70 and an FVC< LLN.
b Values were calculated using a single Cox regression mortality model that was adjusted for age, age2, height, sex, ethnicity, smoking
history, BMI, BMI2, BMI3, memory impairment, self-reported health status by time interaction, and chronic conditions.
c Defined by an FEV1/FVC .70 with an FVC LLN.
d Defined by an FEV1/FVC< .70.
1472 C.A. Vaz Fragoso et al.Table 5 provides the mean values for the FEV1/FVC and
the prevalence of ever-smokers and reduced health status
according to FEV1 SR-tile stages among participants with an
FEV1/FVC< .70. Graded relationships were observed, with
an FEV1< 5th SR-tile having the lowest mean value for the
FEV1/FVC and the highest prevalence of ever-smokers and
reduced health status, respectively.
Table 6 provides the FEV1 %Pred values that corresponded
to the 10th and 5th SR-tiles, respectively, for a person of
average height. For each of these SR-tile cut-points, the
%Pred values varied considerably based on age, ethnicity, and
sex. For example, a 65-year oldmale of average height had anTable 4 Adjusted odds ratios for respiratory symptoms accordi
versus those with normal pulmonary function (NZ 2313).a
Spirometric category No. (%) of participants No. (%)
with re
Normal pulmonary
functiond
1483 (64.1) 614 (41
Airflow limitatione FEV1 SR-tile
50th 116 (5.0) 46 (39
30the49th 122 (5.3) 42 (34
10the29th 281 (12.2) 124 (44
5the9th 132 (5.7) 78 (59
<5th 179 (7.7) 123 (68
Abbreviations: FEV1Z forced expiratory volume in 1 s; SR-tileZ
CIZ confidence interval; BMIZ body mass index; LLNZ lower limit o
a 80 participants (3.2%) had missing covariates and 87 (3.5%) were ex
FVC .70 and an FVC< LLN.
b 1027 participants had respiratory symptoms (i.e., cough or sputum
c Values were calculated using a single logistic regression model t
history, BMI, memory impairment, self-reported health status, and ch
d Defined by an FEV1/FVC .70 with an FVC LLN.
e Defined by an FEV1/FVC< .70.FEV1 value at the 5th SR-tile that ranged from 51%Pred in
African-Americans to 69%Pred in white Americans.
Discussion
In a large, nationally representative sample of community-
living persons aged 65e80 years, we found that a two-part
spirometric definition of COPD that includes an FEV1/
FVC< .70, with FEV1 cut-points at the 10th and 5th SR-tiles,
identifies individuals with an increased prevalence of
respiratory symptoms and an increased risk of death,
respectively.ng to FEV1 SR-tile, among participants with airflow limitation
of participants
spiratory symptoms
Respiratory symptoms
versus no symptomsb
Odds Ratio (95% CI)c p-value
.4) 1.00 e
.7) 1.09 (0.78, 1.51) .600
.4) .89 (0.62, 1.29) .544
.1) 1.24 (0.96, 1.59) .094
.1) 2.14 (1.45, 3.17) <.001
.7) 2.71 (1.91, 3.86) <.001
standardized residual percentile; FVCZ forced vital capacity;
f normal.
cluded because of restrictive pulmonary physiology, i.e., an FEV1/
production, wheezing, or dyspnea), while 1286 had none.
hat was adjusted for age, age2, height, sex, ethnicity, smoking
ronic conditions.
Table 5 Mean FEV1/FVC values and prevalence of ever-smokers and reduced health status among participants with normal
pulmonary function and airflow limitation, staged according to FEV1 SR-tile.
Spirometric category No. (%) Mean FEV1/FVC No. (%) of ever-smokers
among participants
No. (%) of participants
with reduced health
statusa
Normal pulmonary
functionb
1488 (64.2) .78 686 (46.1) 496 (33.3)
Airflow limitationc FEV1 SR-tile
50th 116 (5.0) .67 62 (53.4) 31 (26.7)
30the49th 122 (5.3) .66 87 (71.3) 23 (18.8)
10the29th 281 (12.1) .63 201 (71.5) 80 (28.5)
5the9th 133 (5.7) .60 107 (80.4) 46 (34.6)
<5th 179 (7.7) .54 147 (82.1) 74 (41.3)
a Based on self-report of fair-to-poor health status.
b Defined by an FEV1/FVC .70 with an FVC LLN.
c Defined by an FEV1/FVC< 0.70.
COPD in older persons 1473Our strategy for defining COPD has a strong clinical and
physiological basis. First, we have established spirometric
cut-points that are associated with important clinical
measures.25 All-cause mortality is considered the most
definitive health outcome, and was the primary endpoint in
landmark studies of oxygen therapy in COPD.25 In addition,
respiratory symptoms are the most common and distressing
feature of COPD.25 Second, we have evaluated the FEV1 as
an SR-tile rather than %Pred.4,9,13 Because it does not
consider the spread of the reference data, reporting the
FEV1 as %Pred incorrectly assumes that a given value is
equivalent for persons of different age, height, sex, and
ethnicity.16,17 The SR-tile method yields, however, a value
that is applicable to all persons because it considers the
spread of the reference data.16,17 To illustrate, for an
NHANES III participant of average height, we found that
FEV1 values at the 5th SR-tile varied from 51%Pred to
77%Pred, depending on the ethnicity, sex, and age of the
individual; see Table 6. In contrast to our proposed
strategy, current guidelines for COPD recommend spiro-
metric cut-points that have not been clinically validated
among older persons, and report the FEV1 as %Pred.
4,9,13
Our results also help to clarify the best approach for
establishing a critical threshold for the FEV1/FVC ratio, asTable 6 FEV1 %Pred values corresponding to the 10th and 5th S
individual of average height.a
FEV1 SR-tile
cut-points
FEV1 %Pred values
White African-Ameri
Male Female Maleb
65 years 80 years 65 years 80 years 65 years 80 y
10th 79 73 79 73 70 70
5th 69 61 74 67 51 51
FEV1Z forced expiratory volume in 1 s; %PredZ percent predicted, ca
residual percentile, calculated as (measured predicted)/residual st
a The FEV1 predicted values were calculated from sex- and ethnic-sp
were calculated from the SR-tile equation.
b Does not vary by age because the regression equations for African-A
(age was not a significant predictor variable).part of a spirometric definition of COPD. We found that
a fixed-ratio at a threshold of .70 is associated with an
increased risk of death, which is consistent with GOLD
guidelines.4 Among persons with an FEV1/FVC ratio below
this critical threshold, we established COPDdin contrast to
GOLD and other spirometric guidelines4,9,13don the basis of
FEV1 SR-tile cut-points that were defined by mortality risk
and the prevalence of respiratory symptoms. Using this
strategy, 7.7% of our study population had a severe form of
COPD, defined by an FEV1/FVC< .70 and an FEV1< 5th SR-
tile, which conferred an increased risk of death and an
increased prevalence of respiratory symptoms. This
subgroup also had the highest prevalence of smoking
exposure and reduced health status, and the lowest mean
value for the FEV1/FVC. Participants with an FEV1/
FVC< .70 and an FEV1 at the 5the9th SR-tiles, representing
5.7% of the study population, had a milder form of COPD,
which conferred an increased prevalence of respiratory
symptoms but not an increased risk of death. This subgroup
had the second highest prevalence of smoking exposure and
reduced health status, and the second lowest mean value
for the FEV1/FVC.
Because neither the risk of death nor prevalence of
respiratory symptoms was elevated, we would argue thatR-tiles, stratified according to ethnicity, sex, and age, in an
can Mexican-American
Female Maleb Female
ears 65 years 80 years 65 years 80 years 65 years 80 years
80 72 80 80 72 71
77 68 59 59 69 67
lculated as [(measured/predicted) 100]; SR-tileZ standardized
andard deviation.
ecific regression equations e see appendix; while measured values
merican and Mexican-American males do not include an age term
1474 C.A. Vaz Fragoso et al.participants with an FEV1/FVC< .70 but an FEV1 10th SR-
tile have airflow limitation, but not COPD. Although longi-
tudinal studies are needed, this latter group may be
heterogeneous, including persons who simply have normal
age-related increases in airflow limitation and those who
will experience declines in pulmonary function over time
(i.e., transition to COPD).26
As compared with current guidelines,4,9,13 our two-part
spirometric definition posits that a reduced FEV1/FVC,
although necessary for defining airflow limitation, is insuf-
ficient to establish a diagnosis of COPD. Developmentally,
after achieving peak pulmonary function at about 20 years
of age, airflow limitation increases with age,27 principally
due to increasing rigidity of the chest wall and decreasing
elastic recoil of the lung.35 Although COPD is also charac-
terized by airflow limitation, this effect is due to small
airways’ disease and parenchymal destruction.4,36 Conse-
quently, a reduced FEV1/FVC as a measure of airflow limi-
tation can be caused by normal aging and/or clinically-
significant pathology.7,8 To make this distinction, it is
necessary to consider the FEV1 because it is associated with
COPD-related airway inflammation in persons with estab-
lished airflow limitation.36 Consequently, among older
persons, our spirometric strategy likely reduces potential
misclassification of COPD, as evidenced by an overall
prevalence (13.4%) that is more clinically realistic than that
generated by GOLD guidelines (34.5%).
If routinely implemented, our spirometric strategy for
defining COPD could lead to improvements in patient care.
For example, with GOLD guidelines, exercise intolerance in
an older patient who has coexisting cardiopulmonary risk
factors, anemia, and a history of physical inactivity might
be attributed primarily to COPD instead of to one or more
of the patient’s comorbid conditions. Because cut-points
are based on clinical measures relevant to COPD, our
spirometric strategy could lead to a more targeted use of
COPD-specific pharmacotherapy and, as a result, reduce
the frequency of medication-related adverse events.18
We recognize potential limitations to our study. First,
a threshold based on the LLN for the FEV1/FVC could not
be reliably determined. Unlike the FEV1 and FVC, regres-
sion equations for the FEV1/FVC lack explanatory ability in
older persons. This may be attributable to age-related
increases in lung function variability, leading to normal
values for the FEV1/FVC that range widely and are signifi-
cantly skewed e in comparison to the FEV1 and FVC alone.
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Moreover, because prior work has shown that elderly persons
with an FEV1/FVC< .70 but >LLN have an increased risk of
death,8 the clinical validity of the LLN is uncertain. Our
inability to calculate the LLN of the FEV1/FVC likely had little
effect on our estimate of COPD prevalence, since our
strategy relies ultimately on the FEV1 SR-tile to establish
a diagnosis.
Second, the cut-points thatwe identified for the FEV1/FVC
and FEV1 SR-tile were based on a single cohort of older
persons. Further validation of these cut-points, with an
expanded array of clinically relevant outcomes (including
health care utilization), will be required in other cohorts of
older persons, as well as in other age groups.
Third, evaluating an outcome based on all-cause
mortality rather than COPD-specific mortality might be
considered a limitation. Prior work has shown, however,that COPD is commonly underreported as a cause of death,
even among patients with symptomatic COPD.28 Further-
more, COPD increases the risk of death from cardiovascular
disease and lung cancer, and the number of deaths from
these causes is much greater than those from respiratory
disease among patients with COPD.28e30
Fourth, our spirometric definition of mild COPD is based
on the presence of respiratory symptoms, which are not
necessarily specific to COPD.37 Nonetheless, respiratory
symptoms are the most distressing feature of COPD and can
lead to disability and increased healthcare utilization.25,37
In addition, the graded relationship observed for the pres-
ence of respiratory symptoms across the FEV1 SR-tile stages
(Table 4) enhances the validity of our spirometric definition
of COPD.
Finally, because spirometry in NHANES III was not
obtained after a bronchodilator, we could not assess
reversibility, a recommended criterion for defining COPD.4
It is unlikely, however, that the absence of information on
‘‘reversibility’’ had a meaningful effect on our results,
because 1) persons with self-reported asthma were
excluded, 2) prior work has shown that only 3% of
abnormal prebronchodilator FEV1/FVC ratios normalize in
response to a bronchodilator,31,32 and 3) bronchodilator
reversibility, as defined by the FEV1 response, is neither
a sufficient criterion to exclude COPD nor an independent
predictor of mortality.33,34 Nevertheless, we acknowledge
that our spirometric analyses may have included a small
number of participants with asthma, either as a sole form
of obstructive airways disease or comorbidity.
In conclusion, among older persons, we are proposing
a revised spirometric definition of COPD that identifies
individuals with an increased prevalence of respiratory
symptoms and an increased risk of death. If confirmed in
other populations of older persons, this definition of COPD
could lead to improvements in patient care.
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Appendix Multiple regression models for spirometric measures in ‘‘healthy’’ NHANES III participants aged 65e80 years.a,b
Ethnicity/sex N Spirometric measure InterceptPRD InterceptLLN Age Age
2 Height Height2 RSD R2
White Males 112 FEV1 3.0439 2.9736 .0444 e .0548 e .5299 .42
FVC 4.1667 4.0716 .0439 e .0750 e .6421 .45
White Females 215 FEV1 2.0299 1.9934 .0314 e .0228 e .3501 .28
FVC 2.6875 2.6406 .0361 e .0369 e .4840 .28
African-American Males 33 FEV1 2.5797 2.3653 e e .0484 e .6396 .14
FVC 3.4461 3.1946 e e .0712 e .8032 .18
African-American Females 75 FEV1 1.7095 1.6558 .0384 e .0348 e .3156 .42
FVC 2.2253 2.1493 .0447 e .0459 e .4067 .41
Mexican-American Males 32 FEV1 2.8544 2.6667 e e .0336 e .5302 .15
FVC 3.8422 3.6331 e e .0571 e .6374 .26
Mexican-American Females 85 FEV1 1.8013 1.7271 .0322 .0052 .0329 e .3620 .31
FVC 2.4082 2.3044 .0323 .0067 .0448 .0011 .4652 .33
Abbreviations: NHANES IIIZ The third national health and nutrition examination survey; FEV1Z forced expiratory volume in 1 s;
FVCZ forced vital capacity; InterceptPRDZ predicted intercept; InterceptLLNZ lower limit of normal for the intercept (i.e., inter-
ceptPRD [1.645 standard error of the interceptPRD]); AgeZ years; heightZ cm; RSDZ standard deviation of the residual; R2Z the
explained variation; eZ represent effects that were not statistically significant at the .05 level (all other listed effects were significant
at p< .05).
a ‘‘Healthy’’ included never-smokers, with no chronic conditions and no respiratory symptoms.
b To enhance interpretability, the predictor variables of age and height were centered, i.e., for each participant the mean spirometric
value was subtracted from the measured value.
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